[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f155k3eptmmpi8":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":28,"specialties":33,"cover":11},920,"ml8abiaky78alcf6nkvc5w5g","cytochrome-p450-2d6-inducers","Cytochrome P450 2D6 Inducers",null,"CYP2D6 is a cytochrome P450 monooxygenase that oxidises fatty acids, steroids and retinoids, inserting one atom of molecular oxygen into the substrate and reducing the second to water with two electrons supplied by NADPH through cytochrome P450 reductase. Drugs in this class induce that activity, so a co-administered substrate of the pathway is cleared faster and its exposure falls; FDA defines an inducer by that fall, calling an index inducer strong at a decrease in the AUC of a sensitive substrate of at least 80 percent and moderate at 50 to under 80 percent. CYP2D6 induction is poorly established: the only induction UniProt records for this enzyme is by pregnancy, and FDA's tables of in vitro and clinical index inducers carry no CYP2D6 row at all. A drug belongs here because its recorded effect on CYP2D6 is induction, not inhibition; as MED-RT populates the class, its one member is oritavancin.",[14,20,24],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"CYP2D6 as a cytochrome P450 monooxygenase metabolising fatty acids, steroids and retinoids; the monooxygenase mechanism; INDUCTION: 'By pregnancy'.","UniProtKB P10635","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP10635.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"'Strong and moderate index inducers are drugs that decrease the AUC of sensitive substrates of a given metabolic pathway by >=80 percent and >=50 to \u003C80 percent, respectively.' - the FDA definition of an inducer, stated as a fall in substrate exposure. Also: Table 1-3 (in vitro inducers) and Table 2-3 (clinical index inducers) have rows for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP3A only - there is no CYP2D6 row.","FDA, Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers","https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"Class membership: oritavancin.","RxNav RxClass class members (MED-RT), classId N0000191267","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000191267&relaSource=MEDRT&rela=has_MoA",[29],{"id":30,"documentId":31,"slug":32,"name":32,"active_ingredient":11,"dosage_form":11,"administration_route":11},1769,"axusfveu24u0fdfhtc89rtbm","phenytoin",[]]